The breast cancer gene 1 (BRCA1) is a tumor suppressor, and mutations or epigenetic inactivation will increase the risk of breast cancer oncogenesis. The current research aimed to explore the relationship between BRCA1 expression, prognosis, and tumor immunity in hepatocellular carcinoma (HCC). In this study, BRCA1 expression was analyzed via multiple online databases and its association with clinical characteristics, prognosis and genetic alterations was identified using the original The Cancer Genome Atlas-liver hepatocellular carcinoma cohorts. DNA methylation sites and their prognostic values were analyzed using MethSurv. The correlations between BRCA1 and immune infiltration were investigated via Tumor Immune Estimation Resource. As results, BRCA1 was significantly upregulated in tumor tissues in multiple HCC cohorts. Besides, high BRCA1 expression was correlated with race, advanced T stage, clinical stage, poor tumor grade, MSI status, and worse prognosis. Notably, BRCA1 expression was positively correlated with infiltration levels of B cells, CD4+ T cells, CD8+ T cells, neutrophils, macrophages, and dendritic cells. The current findings imply that BRCA1 is associated with prognosis and immune infiltration, laying foundations for in-depth research on the role of BRCA1 in HCC.
Get full access to this article
View all access options for this article.
References
1.
AgalliuI., GernR., LeanzaS., and BurkR.D. (2009). Associations of high-grade prostate cancer with BRCA1 and BRCA2 founder mutations. Clin Cancer Res, 15, 1112–1120.
2.
AlmangushA., RuuskanenM., HagstromJ., HirvikoskiP., TommolaS., KosmaV.M., et al. (2018). Tumor-infiltrating lymphocytes associate with outcome in nonendemic nasopharyngeal carcinoma: a multicenter study. Hum Pathol, 81, 211–219.
3.
BigagliE., De FilippoC., CastagniniC., TotiS., AcquadroF., GiudiciF., et al. (2016). DNA copy number alterations, gene expression changes and disease-free survival in patients with colorectal cancer: a 10 year follow-up. Cell Oncol (Dordr), 39, 545–558.
4.
CeramiE., GaoJ., DogrusozU., GrossB.E., SumerS.O., AksoyB.A., et al. (2012). The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov, 2, 401–404.
5.
ChenT.H., ZhangY.C., TanY.T., AnX., XueC., DengY.F., et al. (2017). Tumor-infiltrating lymphocytes predict prognosis of breast cancer patients treated with anti-Her-2 therapy. Oncotarget, 8, 5219–5232.
6.
ChenW., WangJ., LiX., LiJ., ZhouL., QiuT., et al. (2013). Prognostic significance of BRCA1 expression in gastric cancer. Med Oncol 30,423.
7.
ChenY., ShiC., and GuoQ. (2016). TNRC9 rs12443621 and FGFR2 rs2981582 polymorphisms and breast cancer risk. World J Surg Oncol 14,50.
8.
ChoiW., OchoaA., McConkeyD.J., AineM., HoglundM., KimW.Y., et al. (2017). Genetic alterations in the molecular subtypes of bladder cancer: illustration in the cancer genome atlas dataset. Eur Urol, 72, 354–365.
9.
De LucaP., and De SierviA. (2016). Critical role for BRCA1 expression as a marker of chemosensitivity response and prognosis. Front Biosci (Elite Ed), 8, 72–83.
10.
De StefanoF., ChaconE., TurciosL., MartiF., and GedalyR. (2018). Novel biomarkers in hepatocellular carcinoma. Dig Liver Dis, 50, 1115–1123.
11.
DenkertC., von MinckwitzG., Darb-EsfahaniS., LedererB., HeppnerB.I., WeberK.E., et al. (2018). Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncol, 19, 40–50.
12.
DingJ., and WangH. (2014). Multiple interactive factors in hepatocarcinogenesis. Cancer Lett, 346, 17–23.
13.
FanS., TianT., LvX., LeiX., YangZ., LiuM., et al. (2020). lncRNA CISAL inhibits BRCA1 transcription by forming a tertiary structure at its promoter. iScience 23,100835.
14.
GaoJ., AksoyB.A., DogrusozU., DresdnerG., GrossB., SumerS.O., et al. (2013). Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 6,pl1.
15.
GiannakisM., MuX.J., ShuklaS.A., QianZ.R., CohenO., NishiharaR., et al. (2016). Genomic correlates of immune-cell infiltrates in colorectal carcinoma. Cell Rep 17,1206.
16.
GuY., LiX., BiY., ZhengY., WangJ., LiX., et al. (2020). CCL14 is a prognostic biomarker and correlates with immune infiltrates in hepatocellular carcinoma. Aging (Albany NY), 12, 784–807.
17.
HedauS., BatraM., SinghU.R., BhartiA.C., RayA., and DasB.C. (2015). Expression of BRCA1 and BRCA2 proteins and their correlation with clinical staging in breast cancer. J Cancer Res Ther, 11, 158–163.
18.
KingM.C., MarksJ.H., MandellJ.B., and New York Breast Cancer StudyG. (2003). Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science, 302, 643–646.
19.
KwongA., ShinV.Y., HoJ.C., KangE., NakamuraS., TeoS.H., et al. (2016). Comprehensive spectrum of BRCA1 and BRCA2 deleterious mutations in breast cancer in Asian countries. J Med Genet, 53, 15–23.
20.
LanczkyA., NagyA., BottaiG., MunkacsyG., SzaboA., SantarpiaL., et al. (2016). miRpower: a web-tool to validate survival-associated miRNAs utilizing expression data from 2178 breast cancer patients. Breast Cancer Res Treat, 160, 439–446.
21.
LeD.T., DurhamJ.N., SmithK.N., WangH., BartlettB.R., AulakhL.K., et al. (2017). Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science, 357, 409–413.
22.
LiB., SeversonE., PignonJ.C., ZhaoH., LiT., NovakJ., et al. (2016). Comprehensive analyses of tumor immunity: implications for cancer immunotherapy. Genome Biol 17,174.
23.
LiT., FanJ., WangB., TraughN., ChenQ., LiuJ.S., et al. (2017). TIMER: a web server for comprehensive analysis of tumor-infiltrating immune cells. Cancer Res, 77, e108–e110.
24.
LianQ., WangS., ZhangG., WangD., LuoG., TangJ., et al. (2018). HCCDB: a database of hepatocellular carcinoma expression atlas. Genom Proteom Bioinform, 16, 269–275.
25.
LiuJ., LichtenbergT., HoadleyK.A., PoissonL.M., LazarA.J., CherniackA.D., et al. (2018). An integrated TCGA pan-cancer clinical data resource to drive high-quality survival outcome analytics. Cell, 173, 400.e11–416.e11.
26.
MeiJ., HaoL., LiuX., SunG., XuR., WangH., et al. (2019). Comprehensive analysis of peroxiredoxins expression profiles and prognostic values in breast cancer. Biomark Res 7,16.
27.
ModhukurV., IljasenkoT., MetsaluT., LokkK., Laisk-PodarT., and ViloJ. (2018). MethSurv: a web tool to perform multivariable survival analysis using DNA methylation data. Epigenomics, 10, 277–288.
28.
RomagnoloA.P., RomagnoloD.F., and SelminO.I. (2015). BRCA1 as target for breast cancer prevention and therapy. Anticancer Agents Med Chem, 15, 4–14.
29.
SavageK.I., and HarkinD.P. (2015). BRCA1, a ‘complex’ protein involved in the maintenance of genomic stability. FEBS J, 282, 630–646.
30.
ShanJ., DsouzaS.P., BakhruS., Al-AzwaniE.K., AsciertoM.L., SastryK.S., et al. (2013). TNRC9 downregulates BRCA1 expression and promotes breast cancer aggressiveness. Cancer Res, 73, 2840–2849.
31.
ShilpaV., BhagatR., PremalataC.S., PallaviV.R., RameshG., and KrishnamoorthyL. (2014). BRCA1 promoter hypermethylation and protein expression in ovarian carcinoma—an Indian study. Tumour Biol, 35, 4277–4284.
32.
SiegelR.L., MillerK.D., and JemalA. (2020). Cancer statistics, 2020. CA Cancer J Clin, 70, 7–30.
33.
SunC.C., LiS.J., HuW., ZhangJ., ZhouQ., LiuC., et al. (2019). Comprehensive analysis of the expression and prognosis for E2Fs in human breast cancer. Mol Ther, 27, 1153–1165.
34.
TaiC.S., LinY.R., TengT.H., LinP.Y., TuS.J., ChouC.H., et al. (2017). Haptoglobin expression correlates with tumor differentiation and five-year overall survival rate in hepatocellular carcinoma. PLoS One 12,e0171269.
35.
TaronM., RosellR., FelipE., MendezP., SouglakosJ., RoncoM.S., et al. (2004). BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer. Hum Mol Genet, 13, 2443–2449.
36.
ThomasL.E., WinstonJ., RadE., MortM., DoddK.M., TeeA.R., et al. (2015). Evaluation of copy number variation and gene expression in neurofibromatosis type-1-associated malignant peripheral nerve sheath tumours. Hum Genom 9,3.
37.
TsibulakI., WieserV., DegasperC., ShivalingaiahG., WenzelS., SprungS., et al. (2018). BRCA1 and BRCA2 mRNA-expression prove to be of clinical impact in ovarian cancer. Br J Cancer, 119, 683–692.
38.
UhlenM., FagerbergL., HallstromB.M., LindskogC., OksvoldP., MardinogluA., et al. (2015). Proteomics. Tissue-based map of the human proteome. Science 347,1260419.
39.
UhlenM., OksvoldP., FagerbergL., LundbergE., JonassonK., ForsbergM., et al. (2010). Towards a knowledge-based Human Protein Atlas. Nat Biotechnol, 28, 1248–1250.
40.
WangG.H., ZhaoC.M., HuangY., WangW., ZhangS., and WangX. (2018). BRCA1 and BRCA2 expression patterns and prognostic significance in digestive system cancers. Hum Pathol, 71, 135–144.
41.
WenW.X., and LeongC.O. (2019). Association of BRCA1- and BRCA2-deficiency with mutation burden, expression of PD-L1/PD-1, immune infiltrates, and T cell-inflamed signature in breast cancer. PLoS One 14,e0215381.
42.
XuY., OuyangT., LiJ., WangT., FanZ., FanT., et al. (2018). Predictive value of BRCA1/2 mRNA expression for response to neoadjuvant chemotherapy in BRCA-negative breast cancers. Cancer Sci, 109, 166–173.
43.
YuanQ., SunN., ZhengJ., WangY., YanX., MaiW., et al. (2019). Prognostic and Immunological Role of FUN14 Domain Containing 1 in Pan-Cancer: friend or Foe?. Front Oncol 9,1502.
44.
ZhangW., LuoJ., ChenF., YangF., SongW., ZhuA., et al. (2015). BRCA1 regulates PIG3-mediated apoptosis in a p53-dependent manner. Oncotarget, 6, 7608–7618.
45.
ZhangW., LuoJ., YangF., WangY., YinY., StromA., et al. (2016). BRCA1 inhibits AR-mediated proliferation of breast cancer cells through the activation of SIRT1. Sci Rep 6,22034.
46.
ZhengH., ZhangG., ZhangL., WangQ., LiH., HanY., et al. (2020). Comprehensive review of web servers and bioinformatics tools for cancer prognosis analysis. Front Oncol 10,68.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
